Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,010.31 -4.18 (-0.41%)

Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

3 Growth Stocks to Invest $1,000 Right Now ↗

September 29, 2025

Market leaders riding secular tailwinds are likely to be profitable long-term investments.

Via The Motley Fool

Topics Artificial Intelligence

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

Why Guardant Health (GH) Stock Is Trading Up Today

September 29, 2025

Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 1.6% in the morning session after the U.S. Food and Drug Administration (FDA) approved its Guardant360® CDx blood test as a companion...

Via StockStory

Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies ↗

September 26, 2025

Via Stocktwits

Topics Government

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

This Is What Whales Are Betting On Eli Lilly ↗

September 29, 2025

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE: LLY). And retail traders should know. We noticed this today when the trades showed up on publicly available...

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.

Via Benzinga

Topics Government World Trade

September 29, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring? ↗

September 28, 2025

The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.

Via The Motley Fool

Where Will Recursion Pharmaceuticals Be in 5 Years? ↗

September 28, 2025

Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?

Via The Motley Fool

Topics Animal Testing Artificial Intelligence

Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data

September 27, 2025

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This...

Via MarketMinute

Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet? ↗

September 27, 2025

The company continues to improve its pipeline.

Via The Motley Fool

Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility

September 26, 2025

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025....

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Healthcare Sector Reels: A Deep Dive into Thursday's -1.67% Plunge

September 26, 2025

The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets....

Via MarketMinute

Topics Economy

Amgen Expands US Manufacturing Network Amid New Tariff Policy ↗

September 26, 2025

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Via Benzinga

Topics Government World Trade

Your AstraZeneca Medicine Could Be Cheaper As Much As 70% ↗

September 26, 2025

AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent...

Via Benzinga

Consumers Splurge, Intel, GlobalFoundries, Lilly, Paccar, American Woodmark Benefit From New Tariffs ↗

September 26, 2025

To gain an edge, this is what you need to know today.

Via Benzinga

Stock Market Soars: Inflation Data Aligns with Expectations, Igniting Hopes for Continued Fed Easing

September 26, 2025

New York, NY – September 26, 2025 – U.S. stock market futures, including the Dow, S&P 500, and Nasdaq, registered notable advances today, signaling a robust open after the release of August's inflation...

Via MarketMinute

Topics Bonds Economy Government

3 Strong-Buy Dividend Growth Stocks ↗

September 26, 2025

All three of these stocks pay fast-growing dividends.

Via The Motley Fool

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst ↗

September 26, 2025

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly...

Via Benzinga

Topics Government World Trade

FDA Approves Eli Lilly's Drug For Advanced Breast Cancer ↗

September 26, 2025

Eli Lilly secured FDA approval for breast cancer drug Inluriyo and EU clearance for Alzheimer's therapy Kisunla following strong Phase 3 data.

Via Benzinga

Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock? ↗

September 26, 2025

The pharmaceutical giant is again plunging headfirst into weight-loss drug development.

Via The Motley Fool

Topics Intellectual Property

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know. ↗

September 26, 2025

Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.

Via The Motley Fool

Why Is Eli Lilly’s Stock Rising Premarket? ↗

September 26, 2025

The European Commission cleared its Alzheimer’s drug Kisunla, adding another country to the company’s list where the once-monthly therapy is approved.

Via Stocktwits

Topics Government World Trade

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

Eli Lilly (LLY) Stock Trades Down, Here Is Why

September 25, 2025

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was...

Via StockStory

Topics Artificial Intelligence

Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move? ↗

September 25, 2025

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it...

Via Benzinga

AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection

September 25, 2025

In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July...

Via MarketMinute

Topics Artificial Intelligence

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

All News about Eli Lilly

Starting at $3.75/week.

Subscribe Today